NL-OMON26222招募中不适用
A phase I Clinical Trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS).
Radboud University Nijmegen Medical Centre0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. MDS (including the non-proliferative form of CMML, i.e. CMML with a WBC count < 12,0 x 109) /L with < 30% blast cells in the bone marrow and with < 5% circulating blasts);
- •2. IPSS: Intermediate Risk-2 or High Risk;
排除标准
- •1. IPSS: Low risk and Intermediate-1 category;
- •2. Candidates for allogeneic stem cell transplantation;
研究者
相似试验
尚未招募
不适用
A phase I clinical trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS)myelodysplasiamyelodysplastic syndroom10018865NL-OMON30154niversitair Medisch Centrum Sint Radboud18
招募中
1 期
A Study of ICP-033 in Patients With Advanced Solid TumorsPatients With Advanced Solid TumorsNCT05367232Beijing InnoCare Pharma Tech Co., Ltd.60
Unknown
1 期
A Study of CSPCHA131 in Patients With Advanced Solid TumorAdvanced Solid TumorsNCT04325711CSPC ZhongQi Pharmaceutical Technology Co., Ltd.100
已完成
1 期
Mesenchymal Stem Cells Transplantation in newly diagnosed Type-1 Diabetes PatientsDiabetes.Insulin-dependent diabetes mellitusIRCT2016070428786N1Royan Institute20
招募中
1 期
A Phase 1 Study of BB102 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06258408Broadenbio Ltd., Co.78